{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:56:25Z","timestamp":1793922985225,"version":"4.8.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in interaction with background diuretic therapy in patients with heart failure and preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of empagliflozin in combination with background diuretic therapy and the association of empagliflozin with the need for conventional diuretics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a post hoc analysis of the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved). EMPEROR-Preserved was a phase 3, randomized, placebo-controlled, double-blind clinical trial conducted from March 2017 to April 2021. Patients with class II to IV heart failure and left ventricular ejection fraction greater than 40% were included. Of 5988 patients enrolled, 5815 (97.1%) had baseline data on diuretic use and were included in this analysis, which was conducted from November 2021 to August 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants in EMPEROR-Preserved were randomized to empagliflozin or placebo. In this analysis, participants were divided into 4 subgroups: no diuretics and furosemide-equivalent diuretic dose of less than 40 mg, 40 mg, and greater than 40 mg at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The main outcomes of interest were first hospitalization for heart failure (HHF) or cardiovascular death (CV death) and its components. Association of empagliflozin vs placebo with outcomes by baseline diuretic status (no diuretic vs any dose) and dose (no diuretic, &amp;amp;lt;40 mg, 40 mg, and &amp;amp;gt; 40mg) was assessed. Association of empagliflozin use with changes in diuretic therapy was also studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 5815 patients (mean [SD] age, 71.9 [9.4] years; 2594 [44.6%] female) with known baseline diuretic use, 1179 (20.3%) were not taking diuretics, 1725 (29.7%) were taking less than 40 mg, 1772 (30.5%) were taking 40 mg, and 1139 (19.6%) were taking greater than 40 mg. In the placebo arm, patients with higher diuretic doses had worse outcomes. Empagliflozin decreased the risk of HHF or CV death, regardless of background diuretic status (hazard ratio [HR], 0.81; 95% CI, 0.70-0.93] for the diuretic group vs HR, 0.72; 95% CI, 0.48-1.06 for the nondiuretic group;\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.58). Similarly, diuretic status was not associated with changes in improvements in first HHF, total HHF, rate of decline in estimated glomerular filtration rate, and Kansas City Cardiomyopathy Questionnaire 23 clinical summary score with empagliflozin. Findings were consistent when patients were categorized by diuretic dose. Empagliflozin was associated with a decreased likelihood of diuretic dose escalation (HR, 0.74; 95% CI, 0.65-0.84) and an increased likelihood of de-escalation (HR, 1.15; 95% CI, 1.02-1.30). Empagliflozin was associated with an increased risk of volume depletion in patients taking diuretics (HR, 1.34; 95% CI, 1.13-1.59).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, treatment with empagliflozin was similar regardless of diuretic use or dose. Empagliflozin use was associated with decreased conventional diuretic dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951\">NCT03057951<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.1090","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T11:33:41Z","timestamp":1684928021000},"page":"640","source":"Crossref","is-referenced-by-count":63,"title":["Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction"],"prefix":"10.1001","volume":"8","author":[{"given":"Javed","family":"Butler","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center, Jackson"},{"name":"Baylor Scott and White Research Institute, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques, Plurith\u00e9matique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"},{"name":"First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Baim Institute for Clinical Research, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kaul","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana L.","family":"Pi\u00f1a","sequence":"additional","affiliation":[{"name":"Central Michigan University, Mount Pleasant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Sumin","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St Michael\u2019s Hospital, University of Toronto, Tortonto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Zaremba-Pechmann","sequence":"additional","affiliation":[{"name":"Elderbrook Solutions on behalf of Boehringer Ingelheim, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas"},{"name":"Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Anker","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"16","key":"hoi230021r1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"hoi230021r2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.800490","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism.","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"hoi230021r3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review.","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"hoi230021r4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ejhf.v22.4","article-title":"Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors.","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi230021r5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cmet.2020.06.014","article-title":"SGLT2 inhibitor: not a traditional diuretic for heart failure.","volume":"32","author":"Verma","year":"2020","journal-title":"Cell Metab"},{"issue":"10","key":"hoi230021r6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/ejhf.v21.10","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial.","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"hoi230021r7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF.","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"hoi230021r8","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi230021r9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial.","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"1","key":"hoi230021r10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi230021r11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi230021r12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review.","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi230021r13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"hoi230021r14","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium.","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi230021r15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ejhf.v24.2","article-title":"Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hoi230021r16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ejhf.2019.21.issue-3","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial.","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi230021r17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ejhf.v25.1","article-title":"Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2805335\/jamacardiology_butler_2023_oi_230021_1688580094.7697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T11:05:07Z","timestamp":1689159907000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2805335"}},"subtitle":["A Post Hoc Analysis of the EMPEROR-Preserved Trial"],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.1090","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}